Top Page
Orasure Technologies
(NASDAQ:OSUR)
Orasure Technologies (OSUR) vs. SPDR S&P 500 ETF (SPY)
Orasure Technologies Business Overview & Revenue Model
Orasure Technologies Earnings Call Summary
Orasure Technologies Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 125.70M | 185.83M | 405.47M | 387.48M | 233.67M | 171.72M |
| Gross Profit | 50.80M | 79.39M | 179.42M | 148.44M | 117.60M | 101.87M |
| EBITDA | -51.50M | -13.55M | 64.35M | 10.29M | 846.00K | 3.44M |
| Net Income | -60.24M | -19.50M | 53.66M | -17.13M | -23.00M | -14.92M |
Balance Sheet | ||||||
| Total Assets | 423.10M | 479.66M | 482.85M | 444.18M | 460.99M | 454.47M |
| Cash, Cash Equivalents and Short-Term Investments | 216.48M | 267.76M | 290.41M | 110.85M | 153.04M | 209.40M |
| Total Debt | 13.46M | 14.60M | 13.50M | 12.55M | 12.27M | 6.13M |
| Total Liabilities | 61.12M | 69.32M | 52.17M | 79.75M | 80.46M | 55.90M |
| Stockholders Equity | 361.98M | 410.34M | 430.67M | 364.43M | 380.53M | 398.57M |
Cash Flow | ||||||
| Free Cash Flow | -43.65M | 23.58M | 131.28M | -111.11M | -83.50M | -23.12M |
| Operating Cash Flow | -39.92M | 27.37M | 141.58M | -47.20M | -35.38M | 5.81M |
| Investing Cash Flow | -7.88M | -39.03M | 66.15M | 21.09M | -5.50M | -14.03M |
| Financing Cash Flow | -11.94M | -4.18M | -3.02M | -3.83M | -2.82M | 92.48M |
Orasure Technologies Technical Analysis
Orasure Technologies Risk Analysis
Orasure Technologies Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
68 Neutral | $94.30M | 8.63 | 30.92% | ― | 23.65% | 120.84% | |
63 Neutral | $172.68M | 15.25 | 9.59% | 2.09% | -12.35% | -17.20% | |
58 Neutral | $247.71M | ― | -170.24% | ― | 19.61% | -3.42% | |
53 Neutral | $178.47M | -39.27 | -21.71% | ― | 22.12% | 69.19% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
46 Neutral | $157.10M | ― | -15.30% | ― | -43.95% | -620.21% | |
41 Neutral | $170.31M | ― | -27.19% | ― | 30.55% | -340.19% |
Orasure Technologies Corporate Events
During the recent earnings call, OraSure Technologies presented a mixed sentiment, highlighting both strategic advancements and financial challenges. The company emphasized its strategic initiatives, including the acquisition of BioMedomics and the renewal of vital public health programs. However, significant revenue declines in both U.S. and International Diagnostics segments, along with ongoing financial losses, suggest a challenging year ahead.
OraSure Technologies, Inc., a prominent player in the healthcare sector, specializes in point-of-need and home diagnostic tests and sample management solutions, aiming to enhance healthcare accessibility and personalization. In its third-quarter 2025 financial results, OraSure reported a total revenue of $27.1 million, reflecting a 32% decline compared to the same period in 2024. Despite the challenges, the company remains optimistic about its growth prospects in 2026, driven by product diversification and new launches. Key financial metrics revealed a 25% decrease in core business revenues and a 34% drop in diagnostics revenue, primarily due to reduced HIV test sales. The company also reported a net loss of $13.7 million for the quarter. OraSure’s strategic initiatives include the acquisition of BioMedomics, which is expected to expand its diagnostic portfolio, and continued collaboration with public health programs. Looking forward, OraSure remains focused on its innovation roadmap and is preparing for the launch of new products in 2026, positioning itself for sustainable growth.
OraSure Technologies announced its financial results for the third quarter of 2025, reporting $27.1 million in revenue. Despite challenges related to funding uncertainties for public health programs, the company is optimistic about returning to growth in 2026 through product diversification and new product launches. The company is focusing on decentralizing diagnostics to make healthcare more accessible and personalized, with upcoming products like the Sherlock over-the-counter molecular self-test for Chlamydia and Gonorrhoeae and the Colli-Pee urine self-collection for sexually transmitted infections.
The most recent analyst rating on (OSUR) stock is a Hold with a $2.50 price target. To see the full list of analyst forecasts on Orasure Technologies stock, see the OSUR Stock Forecast page.
On October 28, 2025, OraSure Technologies announced the resignation of Mara G. Aspinall from her position as director and chair of the Board, with no disputes cited as the cause. John P. Kenny, a current board member, has been appointed as the new chair. Additionally, Steven Boyd has been appointed as a Class II director, effective the same day, and will serve on the Audit Committee and the Nominating and Corporate Governance Committee. Boyd qualifies as an independent director and will receive an initial equity award valued at $100,000, which will vest in two years.
The most recent analyst rating on (OSUR) stock is a Hold with a $3.00 price target. To see the full list of analyst forecasts on Orasure Technologies stock, see the OSUR Stock Forecast page.
OraSure Technologies recently held its second-quarter earnings call, presenting a mixed outlook characterized by both achievements and challenges. While the company reported notable progress in revenue and innovation, it also faced significant hurdles in segments such as Sample Management and international diagnostics, primarily due to external factors. Despite advancements in strategic initiatives, immediate financial impacts remain a concern for the company.